Sartorius is counting on a biopharma boom by 2030
Biologics are expected to account for 57 per cent of pharmaceutical sales
Advertisement
The life science group Sartorius is sharpening its strong focus on biopharma customers and outlines its updated strategy and new mid-term financial targets ahead of today’s Capital Markets Day, setting out a clear path to sustained above-market growth.
“Our resilient business model and success of the past have created a strong foundation. Our future success now depends on how we build on this,” said Dr. Michael Grosse, Chief Executive Officer of Sartorius. “The biopharma industry is in a phase where innovation, speed and reliability matter more than ever. In this more demanding environment, focus becomes critical. By strengthening our core capabilities, building future businesses and further elevating customer experience and efficiency, we want to continue to outperform our markets and create lasting value for customers, partners, suppliers, employees and shareholders alike.”
Sartorius’ refined strategic focus reflects key developments in the biopharmaceutical industry: Biologics account for a growing share of pipelines, approvals, and manufacturing volumes. In 2025, global biopharma revenues surpassed those of traditional therapies for the first time and are projected to reach around 57 percent of global pharma sales by 2030. At the same time, the industry is becoming more complex, with new modalities emerging and increasing cost pressures on health care systems.
Strategic initiatives: Driving portfolio evolution, customer experience and efficiency
To continue its strong growth momentum and expand its established market position in this changing environment, Sartorius has defined a set of strategic initiatives.
Regarding its product portfolio, the company aims to strengthen its core business by reinforcing its leadership positions in mission-critical applications in process intensification, single-use technologies and cell analytics. To leverage future opportunities, Sartorius plans to further develop select emerging businesses, including advanced therapy solutions, advanced cell models, process analytical technologies and analytical characterization and quality control platforms.
Beyond its product offerings, Sartorius will address evolving expectations across the biopharma industry such as shorter lead times, delivery reliability and more simplified interactions. To this end, the company is putting customers even more firmly at the center of its actions as one integrated organization and seeks to elevate its operational efficiency across supply chain performance, product quality, and service levels.
Mid-term ambition: Above-market organic sales revenue growth and margin expansion
Based on its assessment of future market development, Sartorius expects its addressable markets to grow at a rate of approximately 7 to 9 percent per year over the medium term. Within this, the market for Bioprocess Solutions is projected to grow by approximately 8 to 10 percent, the market for Lab Products & Services by approximately 4 to 6 percent annually.
Against this backdrop and building on the company’s leading market position as well as focused strategy, Sartorius introduced a new medium-term ambition for the period from 2027 onwards. Management expects the company to consistently outgrow its addressable markets by around 100 to 200 basis points per year leading to an organic sales revenue growth in constant currencies of 8 to 11 percent per year at group level. This development is expected to be supported by above-market performance of both divisions. For the Bioprocess Solutions Division, Sartorius projects an annual sales revenue increase of 9 to 12 percent in constant currencies, while the Lab Products & Services Division is expected to grow by 5 to 7 percent per year in constant currencies.
At the same time, Sartorius is committed to further expanding its profitability: The underlying EBITDA1 margin at group level is supposed to grow by approximately 50 to 75 basis points per year. Margin expansion is expected to be driven by scale effects, operational improvements, and a growing revenue share of high-margin consumables. For the Bioprocess Solutions Division, management anticipates the EBITDA margin to rise by approximately 60 to 85 basis points per year. For the Lab Products & Services Division margin improvement of approximately 20 to 30 basis points per year is expected, reflecting investments in innovation, digitalization, and future growth platforms.
Other news from the department business & finance
